AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
FAIL · Does not pass the screen
50.50 USD
Price as of 28 Oct 2026Daily close, not a live quote
Screened 2026-10-28 · the tape above runs as of 12:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price50.50 USD at the 28 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans slightly to calls (put/call 0.77)
Last reviewed28 Oct 2026 (1 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 50.50 against the desk's fair-value range, base estimate 95.50, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.77, read 2026-10-24
Ethical does not pass the values gate
Price50.50 USD
Fair value95.50
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown54.92-8.0% to today ✓Accumulation gives way to Markdown first Markdown read since July
2026-08-21Read Accumulation56.98-11.4% to today Markdown gives way to Accumulation with volume flow in agreement
2026-07-02Read Markdown56.07-9.9% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
AnaptysBio, Inc. holds its Markdown at $50.50. Consolidating, no directional conviction, held for 63 days.
As held on the ledger · 2026-10-28
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 63 days
Price at the screen
$50.50
Valuation
N/A trailing · 9.46 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.45
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
3.87%
Below 33%
Interest-bearing debt is just 3.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
20.15%
Below 33%
Cash held in interest-bearing accounts and securities is 20.2% of assets, under the one-third limit.
Pass
Receivables
74.66%
Below 49%
Money owed to the company is 74.7% of assets, above the 49% limit.
Fail
Revenue purity
5.75%
Below 5%
5.8% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
AnaptysBio,'s business is fine, but its receivables are about 75% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ANAB's ethical verdict changes
Today ANAB does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 89.1% margin of safety to the base estimate.
Third-party analyst targets: 8 covering, consensus Strong Buy. The average target sits +57% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical stage bets rarely deliver steady returns
A clinical stage drug developer is like backing an untested runner that has yet to finish a lap. AnaptysBio shows revenue already shrinking eight percent, margins at minus twelve percent and return on equity at minus one hundred fifteen percent. Forward earnings sit at eleven times yet the opportunity rating stays at none, so we pass despite the ethical screen clearing.
The modest ten percent gap to fair value and the strong buy chorus from eleven analysts do not offset a business that is still losing cash with no visible moat. Peak earnings here look distant and fragile rather than a bargain entry point.
Trial outcomes remain binary and funding needs can dilute holders quickly in this sector. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ANAB trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markdown$50.50+5.3%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (11 analysts) rates it strong buy, with a mean price target of $84. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$47.94+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (11 analysts) rates it strong buy, with a mean price target of $84. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$47.94+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (11 analysts) rates it strong buy, with a mean price target of $84. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$47.94-1.6%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (11 analysts) rates it strong buy, with a mean price target of $84. Insiders have been net sellers over the past quarter.
2026-10-19Markdown$48.71+6.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 6.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (11 analysts) rates it strong buy, with a mean price target of $84. Insiders have been net sellers over the past quarter.
2026-10-12Markdown$45.95-16.3%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 73% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (11 analysts) rates it strong buy, with a mean price target of $84. Insiders have been net sellers over the past quarter. Since the last review it its quality tier rose to Gold; its composite score rose.
2026-10-02Markdown · changed$54.92-4.1%Entry 10
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (11 analysts) rates it strong buy, with a mean price target of $84. Since the last review it its composite score rose.
2026-09-08Accumulation$57.29+0.0%Entry 9
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (11 analysts) rates it strong buy, with a mean price target of $84. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-06Accumulation$57.29+0.0%Entry 8
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (11 analysts) rates it strong buy, with a mean price target of $84. It reported earnings in this window, a natural checkpoint for the thesis.
2026-09-05Accumulation$57.29+0.5%Entry 7
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 227%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (11 analysts) rates it strong buy, with a mean price target of $84. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
